279 related articles for article (PubMed ID: 22091400)
1. Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones.
de Castro SL; Batista DG; Batista MM; Batista W; Daliry A; de Souza EM; Menna-Barreto RF; Oliveira GM; Salomão K; Silva CF; Silva PB; Soeiro Mde N
Mol Biol Int; 2011; 2011():306928. PubMed ID: 22091400
[TBL] [Abstract][Full Text] [Related]
2. Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies.
Soeiro Mde N; de Castro SL
Open Med Chem J; 2011; 5():21-30. PubMed ID: 21629508
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
Lara LS; Moreira CS; Calvet CM; Lechuga GC; Souza RS; Bourguignon SC; Ferreira VF; Rocha D; Pereira MCS
Eur J Med Chem; 2018 Jan; 144():572-581. PubMed ID: 29289882
[TBL] [Abstract][Full Text] [Related]
4. Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies.
Soeiro Mde N; Dantas AP; Daliry A; Silva CF; Batista DG; de Souza EM; Oliveira GM; Salomão K; Batista MM; Pacheco MG; Silva PB; Santa-Rita RM; Barreto RF; Boykin DW; Castro SL
Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():301-10. PubMed ID: 19753489
[TBL] [Abstract][Full Text] [Related]
5. Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
Barbosa JMC; Pedra Rezende Y; de Melo TG; de Oliveira G; Cascabulho CM; Pereira ENGDS; Daliry A; Salem KS
Microbiol Spectr; 2022 Feb; 10(1):e0185221. PubMed ID: 35138142
[TBL] [Abstract][Full Text] [Related]
6. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
[TBL] [Abstract][Full Text] [Related]
8. In vitro and In vivo Biological Activity of Two Aryloxy-naphthoquinones in Mice Infected with Trypanosoma cruzi Strains.
Vázquez K; Moreno-Rodríguez A; Domínguez-Díaz LR; Bertrand J; Salas CO; Rivera G; Pérez Cervera Y; Bocanegra-García V
Med Chem; 2024 May; ():. PubMed ID: 38757318
[TBL] [Abstract][Full Text] [Related]
9. Trypanosoma cruzi targets for new chemotherapeutic approaches.
Soeiro MN; de Castro SL
Expert Opin Ther Targets; 2009 Jan; 13(1):105-21. PubMed ID: 19063710
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form--DB1965--against Trypanosoma cruzi infection.
da Silva CF; Batista Dda G; Oliveira GM; de Souza EM; Hammer ER; da Silva PB; Daliry A; Araujo JS; Britto C; Rodrigues AC; Liu Z; Farahat AA; Kumar A; Boykin DW; Soeiro Mde N
PLoS One; 2012; 7(1):e30356. PubMed ID: 22291940
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo experimental models for drug screening and development for Chagas disease.
Romanha AJ; Castro SL; Soeiro Mde N; Lannes-Vieira J; Ribeiro I; Talvani A; Bourdin B; Blum B; Olivieri B; Zani C; Spadafora C; Chiari E; Chatelain E; Chaves G; Calzada JE; Bustamante JM; Freitas-Junior LH; Romero LI; Bahia MT; Lotrowska M; Soares M; Andrade SG; Armstrong T; Degrave W; Andrade Zde A
Mem Inst Oswaldo Cruz; 2010 Mar; 105(2):233-8. PubMed ID: 20428688
[TBL] [Abstract][Full Text] [Related]
12. Trypanocidal activity and selectivity in vitro of aromatic amidine compounds upon bloodstream and intracellular forms of Trypanosoma cruzi.
De Souza EM; da Silva PB; Nefertiti AS; Ismail MA; Arafa RK; Tao B; Nixon-Smith CK; Boykin DW; Soeiro MN
Exp Parasitol; 2011 Feb; 127(2):429-35. PubMed ID: 20971106
[TBL] [Abstract][Full Text] [Related]
13. Experimental and Clinical Treatment of Chagas Disease: A Review.
Sales Junior PA; Molina I; Fonseca Murta SM; Sánchez-Montalvá A; Salvador F; Corrêa-Oliveira R; Carneiro CM
Am J Trop Med Hyg; 2017 Nov; 97(5):1289-1303. PubMed ID: 29016289
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of new 1,2,3-triazoles derived from eugenol and analogues with in vitro and in vivo activity against Trypanosoma cruzi.
Reis RCFM; Dos Santos EG; Benedetti MD; Reis ACC; Brandão GC; Silva GND; Diniz LA; Ferreira RS; Caldas IS; Braga SFP; Souza TB
Eur J Med Chem; 2023 Oct; 258():115622. PubMed ID: 37441850
[TBL] [Abstract][Full Text] [Related]
15. Drug repurposing strategy against Trypanosoma cruzi infection: In vitro and in vivo assessment of the activity of metronidazole in mono- and combined therapy.
Simões-Silva MR; De Araújo JS; Oliveira GM; Demarque KC; Peres RB; D'Almeida-Melo I; Batista DGJ; Da Silva CF; Cardoso-Santos C; Da Silva PB; Batista MM; Bahia MT; Soeiro MNC
Biochem Pharmacol; 2017 Dec; 145():46-53. PubMed ID: 28870526
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations.
Lima DA; Gonçalves LO; Reis-Cunha JL; Guimarães PAS; Ruiz JC; Liarte DB; Murta SMF
Parasit Vectors; 2023 May; 16(1):167. PubMed ID: 37217925
[TBL] [Abstract][Full Text] [Related]
17. Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line.
Alonso-Padilla J; Cotillo I; Presa JL; Cantizani J; Peña I; Bardera AI; Martín JJ; Rodriguez A
PLoS Negl Trop Dis; 2015 Jan; 9(1):e0003493. PubMed ID: 25615687
[TBL] [Abstract][Full Text] [Related]
18. Antiparasitic Activity of
Peres RB; Batista MM; Bérenger ALR; Camillo FDC; Figueiredo MR; Soeiro MNC
Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242777
[TBL] [Abstract][Full Text] [Related]
19. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease.
Gaspar L; Coron RP; KongThoo Lin P; Costa DM; Perez-Cabezas B; Tavares J; Roura-Ferrer M; Ramos I; Ronin C; Major LL; Ciesielski F; Pemberton IK; MacDougall J; Ciapetti P; Smith TK; Cordeiro-da-Silva A
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006180. PubMed ID: 29357372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
